Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECC4703 DDI Trial with Sulfasalazine and Pitavastatin
NCT07726368Phase 1Recruiting
- Sponsor
- Eccogene
- Start
- Aug 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of ECC4703 in non-alcoholic fatty liver disease (NAFLD) (2 cohorts), sponsored by Eccogene. Primary endpoints: Maximum Plasma Concentration of Sulfasalazine, Time to Maximum Plasma Concentration of Sulfasalazine and 6 more. Started Aug 2026; status: recruiting.
02
Drugs
ECC4703
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT07726368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07726368.